GRAIL (NASDAQ:GRAL) CEO Sells 5,000 Shares of Stock

GRAIL, Inc. (NASDAQ:GRAL) CEO Joshua Ofman sold 5,000 shares of GRAIL stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $85.02, for a total transaction of $425,100.00. Following the completion of the transaction, the chief executive officer directly owned 397,271 shares of the company’s stock, valued at approximately $33,775,980.42. This represents a 1.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

GRAIL Stock Down 0.8%

Shares of NASDAQ:GRAL traded down $0.63 on Monday, reaching $79.37. 555,941 shares of the company’s stock were exchanged, compared to its average volume of 781,912. GRAIL, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $118.84. The business’s 50-day moving average is $71.28 and its two-hundred day moving average is $63.22.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. Equities analysts anticipate that GRAIL, Inc. will post -10.41 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its position in shares of GRAIL by 5.2% in the 4th quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock valued at $228,000 after purchasing an additional 133 shares during the period. Comerica Bank increased its stake in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares in the last quarter. Rossby Financial LCC raised its holdings in GRAIL by 25.0% during the 4th quarter. Rossby Financial LCC now owns 1,250 shares of the company’s stock worth $107,000 after buying an additional 250 shares during the period. Prosperity Consulting Group LLC raised its holdings in GRAIL by 6.9% during the 1st quarter. Prosperity Consulting Group LLC now owns 3,881 shares of the company’s stock worth $201,000 after buying an additional 250 shares during the period. Finally, Blair William & Co. IL lifted its stake in GRAIL by 5.3% during the third quarter. Blair William & Co. IL now owns 5,356 shares of the company’s stock valued at $317,000 after buying an additional 268 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GRAL. The Goldman Sachs Group assumed coverage on GRAIL in a research report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Mizuho boosted their price target on shares of GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, TD Cowen restated a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $67.78.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.